Gelonghui November 22丨Hualing Pharmaceutical-B (02552.HK) announcement, which relates to (among others) a commercial cooperation agreement between Hualing Pharmaceutical Technology (Shanghai) Co., Ltd. (“Hualing Shanghai”), a wholly-owned subsidiary of the company, and Bayer Healthcare Co., Ltd. to commercialize dorzagliatin (a type of diabetes treatment) in China and establish a strategic partnership in this regard; (ii) the content (including) the listing of a new drug application for Huatangning (dogleitin tablets, dorzagliatin, HMS5552) Approval; (iii) the content relates to (including) the achievement of a significant milestone in the development of Huatangning and the payment of related milestone payments.
As of November 22, 2023, Hualing Shanghai has received payment from Bayer about HuatangningDevelop a milestone payment of RMB 800 million to achieve an important milestone.